Current and future prospects in the management of granulomatosis with polyangiitis (Wegener’s granulomatosis)

References

• SeoPStoneJHThe antineutrophil cytoplasmic antibody-associated vasculitidesAm J Med2004117395015210387
   PubMed Web of Science ®Google Scholar
• JennetteJCFalkRJBaconPA2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitidesArthritis Rheum20136511123045170
   PubMed Web of Science ®Google Scholar
• HoffmanGSKerrGSLeavittRYWegener granulomatosis: an analysis of 158 patientsAnn Intern Med19921164884981739240
   PubMed Web of Science ®Google Scholar
• FalkRJHoganSCareyTSJennetteJCClinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative NetworkAnn Intern Med19901136566632221646
   PubMed Web of Science ®Google Scholar
• NilesJLBottingerEPSaurinaGRThe syndrome of lung hemorrhage and nephritis is usually an ANCA-associated conditionArch Intern Med19961564404458607730
   PubMed Web of Science ®Google Scholar
• WattsRALaneSEBenthamGScottDGEpidemiology of systemic vasculitis: a ten-year study in the United KingdomArthritis Rheum20004341441910693883
   PubMed Web of Science ®Google Scholar
• BoothADAlmondMKBurnsAOutcome of ANCA-associated renal vasculitis: a 5-year retrospective studyAm J Kidney Dis20034177678412666064
   PubMed Web of Science ®Google Scholar
• FlossmannOBerdenAde GrootKLong-term patient survival in ANCA-associated vasculitisAnn Rheum Dis20117048849421109517
   PubMed Web of Science ®Google Scholar
• MiloslavskyESpecksUMerkelPClinical outcomes of remission induction therapy for severe ANCA-associated vasculitisArthritis Rheum2013652441244923754238
   PubMed Web of Science ®Google Scholar
• PagnouxCHoganSLChinHPredictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohortsArthritis Rheum2008582908291818759282
   PubMed Web of Science ®Google Scholar
• JennetteJCFalkRJHuPXiaoHPathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitisAnnu Rev Pathol2013813916023347350
   PubMed Web of Science ®Google Scholar
• TarziRMCookHTPuseyCDCrescentic glomerulonephritis: new aspects of pathogenesisSemin Nephrol20113136136821839369
   PubMed Web of Science ®Google Scholar
• LudemannJUtechtBGrossWLAnti-cytoplasmic antibodies in Wegener’s granulomatosis are directed against proteinase 3Adv Exp Med Biol19912971411501722626
   PubMedGoogle Scholar
• FalkRJJennetteJCAnti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritisN Engl J Med1988318165116572453802
   PubMed Web of Science ®Google Scholar
• CsernokEErnstMSchmittWBaintonDFGrossWLActivated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivoClin Exp Immunol1994952442508306499
   PubMed Web of Science ®Google Scholar
• HarperLCockwellPAduDSavageCONeutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitisKidney Int2001591729173811318943
   PubMed Web of Science ®Google Scholar
• HattarKvan BurckSBickenbachAAnti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent leukocyte activationJ Leukoc Biol200578992100016006536
   PubMed Web of Science ®Google Scholar
• SavageCOPottingerBEGaskinGPuseyCDPearsonJDAutoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cellsAm J Pathol19921413353421323218
   PubMed Web of Science ®Google Scholar
• RadfordDJSavageCONashGBTreatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesionArthritis Rheum2000431337134510857792
   PubMedGoogle Scholar
• BansalPJTobinMCNeonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvementAnn Allergy Asthma Immunol20049339840115521377
   PubMed Web of Science ®Google Scholar
• LittleMASmythCLYadavRAntineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivoBlood20051062050205815933057
   PubMed Web of Science ®Google Scholar
• XiaoHHeeringaPHuPAntineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in miceJ Clin Invest200211095596312370273
   PubMed Web of Science ®Google Scholar
• LittleMAAl-AniBRenSAnti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune systemPLoS One20127e2862622247758
   PubMed Web of Science ®Google Scholar
• AbdulahadWHKallenbergCGLimburgPCStegemanCAUrinary CD4+ effector memory T cells refect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum2009602830283819714581
   PubMed Web of Science ®Google Scholar
• AbdulahadWHStegemanCALimburgPCKallenbergCGCD4-positive effector memory T cells participate in disease expression in ANCA-associated vasculitisAnn N Y Acad Sci20071107223117804529
   PubMed Web of Science ®Google Scholar
• NogueiraEHamourSSawantDSerum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitisNephrol Dial Transplant2010252209221720100727
   PubMed Web of Science ®Google Scholar
• FreeMEBunchDOMcGregorJANCA-associated vasculitis patients have defective Treg function exacerbated by presence of a suppression-resistant effector populationArthritis Rheum2013651922193323553415
   PubMed Web of Science ®Google Scholar
• MorganMDDayCJPiperKPPatients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cellsImmunology2010130647320113371
   PubMed Web of Science ®Google Scholar
• WildeBThewissenMDamoiseauxJRegulatory B cells in ANCA-associated vasculitisAnn Rheum Dis2013721416141923666929
   PubMed Web of Science ®Google Scholar
• BunchDOMcGregorJGKhandoobhaiNBDecreased CD5(+) B cells in active ANCA vasculitis and relapse after rituximabClin J Am Soc Nephrol2013838239123293123
   PubMed Web of Science ®Google Scholar
• GouSJYuanJChenMYuFZhaoMHCirculating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitisKidney Int20138312913722913983
   PubMed Web of Science ®Google Scholar
• GouSJYuanJWangCZhaoMHChenMAlternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GNClin J Am Soc Nephrol201381884189124115193
   PubMed Web of Science ®Google Scholar
• XiaoHDairaghiDJPowersJPC5a receptor (CD88) blockade protects against MPO-ANCA GNJ Am Soc Nephrol20142522523124179165
   PubMed Web of Science ®Google Scholar
• LyonsPARaynerTFTrivediSGenetically distinct subsets within ANCA-associated vasculitisN Engl J Med201236721422322808956
   PubMed Web of Science ®Google Scholar
• FalkRJJennetteJCANCA disease: where is this field heading?J Am Soc Nephrol20102174575220395376
   PubMed Web of Science ®Google Scholar
• Martinez Del PeroMWalshMLuqmaniRLong-term damage to the ENT system in Wegener’s granulomatosisEur Arch Otorhinolaryngol201126873373921085976
   PubMed Web of Science ®Google Scholar
• HaworthSJSavageCOCarrDHughesJMReesAJPulmonary haemorrhage complicating Wegener’s granulomatosis and microscopic polyarteritisBr Med J (Clin Res Ed)198529017751778
   PubMed Web of Science ®Google Scholar
• HolleJUGrossWLHoll-UlrichKProspective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage?Ann Rheum Dis2010691934119920511614
   PubMed Web of Science ®Google Scholar
• StoneJHWegener’s Granulomatosis Etanercept Trial Research GroupLimited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trialArthritis Rheum2003482299230912905485
   PubMed Web of Science ®Google Scholar
• HoganSLFalkRJChinHPredictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitisAnn Intern Med200514362163116263884
   PubMed Web of Science ®Google Scholar
• ArulkumaranNPeriselnerisNGaskinGInterstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort studyRheumatology (Oxford)2011502035204321873269
   PubMed Web of Science ®Google Scholar
• MukhtyarCFlossmannOHellmichBOutcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task forceAnn Rheum Dis2008671004101017911225
   PubMed Web of Science ®Google Scholar
• WalshMFlossmannOBerdenARisk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum20126454254821953279
   PubMed Web of Science ®Google Scholar
• TomassonGGraysonPCMahrADLavalleyMMerkelPAValue of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis – a meta-analysisRheumatology (Oxford)20125110010922039267
   PubMed Web of Science ®Google Scholar
• TervaertJWvan der WoudeFJFauciASAssociation between active Wegener’s granulomatosis and anticytoplasmic antibodiesArch Intern Med1989149246124652684074
   PubMed Web of Science ®Google Scholar
• FauciASWolffSMWegener’s granulomatosis: studies in eighteen patients and a review of the literatureMedicine (Baltimore)1973525356614748591
   PubMed Web of Science ®Google Scholar
• HeijlCHarperLFlossmannOIncidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trialsAnn Rheum Dis2011701415142121616914
   PubMed Web of Science ®Google Scholar
• RobsonJDollHSuppiahRDamage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trialsAnn Rheum Dis11152013 [Epub ahead of print.]
   Google Scholar
• KnightAAsklingJGranathFSparenPEkbomAUrinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamideAnn Rheum Dis2004631307131115130900
   PubMed Web of Science ®Google Scholar
• FaurschouMSorensenIJMellemkjaerLMalignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patientsJ Rheumatol20083510010517937462
   PubMed Web of Science ®Google Scholar
• Le GuennoGMahrAPagnouxCIncidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitidesArthritis Rheum2011631435144521337321
   PubMedGoogle Scholar
• LittleMANightingalePVerburghCAEarly mortality in systemic vasculitis: relative contribution of adverse events and active vasculitisAnn Rheum Dis2010691036104319574233
   PubMed Web of Science ®Google Scholar
• HolleJUGrossWLLatzaUImproved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decadesArthritis Rheum20116325726620862686
   PubMedGoogle Scholar
• HilhorstMWildeBvan PaassenPImproved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up studyNephrol Dial Transplant20132837337923223225
   PubMed Web of Science ®Google Scholar
• TarziRMPuseyCDVasculitis: risks and rewards of treating elderly patients with vasculitisNat Rev Nephrol2011725325521423250
   PubMed Web of Science ®Google Scholar
• JayneDRasmussenNAndrassyKA randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodiesN Engl J Med2003349364412840090
   PubMed Web of Science ®Google Scholar
• de GrootKHarperLJayneDRPulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trialAnn Intern Med200915067068019451574
   PubMed Web of Science ®Google Scholar
• HarperLMorganMDWalshMPulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-upAnn Rheum Dis20127195596022128076
   PubMed Web of Science ®Google Scholar
• De GrootKRasmussenNBaconPARandomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum2005522461246916052573
   PubMed Web of Science ®Google Scholar
• FaurschouMWestmanKRasmussenNBrief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum2012643472347722614882
   PubMedGoogle Scholar
• JonesRBHarperLBallarinJA randomised trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA associated vasculitisPresse Med201342678 French
   Web of Science ®Google Scholar
• StoneJHMerkelPASpieraRRituximab versus cyclophosphamide for ANCA-associated vasculitisN Engl J Med201036322123220647199
   PubMed Web of Science ®Google Scholar
• JonesRBTervaertJWHauserTRituximab versus cyclophosphamide in ANCA-associated renal vasculitisN Engl J Med201036321122020647198
   PubMed Web of Science ®Google Scholar
• SpecksUMerkelPASeoPEfficacy of remission-induction regimens for ANCA-associated vasculitisN Engl J Med201336941742723902481
   PubMed Web of Science ®Google Scholar
• VoswinkelJMuellerAKraemerJAB lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesionsAnn Rheum Dis20066585986416291812
   PubMed Web of Science ®Google Scholar
• WalshMMerkelPAPehCAPlasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trialTrials2013147323497590
   PubMed Web of Science ®Google Scholar
• ChemoCentryxA Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Renal Vasculitis Available from: http://www.clinicaltrials.gov/ct2/show/NCT01363388?term=NCT01363388&rank=1. NLM identifier: NCT01363388Accessed December 11, 2013
   Google Scholar
• CasianAJayneDPlasma exchange in the treatment of Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitisCurr Opin Rheumatol201123121721124082
   PubMed Web of Science ®Google Scholar
• JayneDRGaskinGRasmussenNRandomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitisJ Am Soc Nephrol2007182180218817582159
   PubMed Web of Science ®Google Scholar
• WalshMCasianAFlossmannOLong-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclearKidney Int20138439740223615499
   PubMed Web of Science ®Google Scholar
• HellmichBFlossmannOGrossWLEULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnn Rheum Dis20076660561717170053
   PubMed Web of Science ®Google Scholar
• RutgersAKallenbergCGRefractory disease in antineutrophil cytoplasmic antibodies associated vasculitisCurr Opin Rheumatol20122424525122410545
   PubMed Web of Science ®Google Scholar
• RollPOstermeierEHaubitzMEfficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID)J Rheumatol2012392153215622984269
   PubMed Web of Science ®Google Scholar
• JayneDRChapelHAduDIntravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activityQJM20009343343910874052
   PubMed Web of Science ®Google Scholar
• MartinezVCohenPPagnouxCIntravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patientsArthritis Rheum20085830831718163506
   PubMed Web of Science ®Google Scholar
• WalshMChaudhryAJayneDLong-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)Ann Rheum Dis2008671322132718055469
   PubMed Web of Science ®Google Scholar
• BirckRWarnatzKLorenzHM15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacyJ Am Soc Nephrol20031444044712538745
   PubMed Web of Science ®Google Scholar
• BoothAHarperLHammadTProspective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitisJ Am Soc Nephrol20041571772114978174
   PubMed Web of Science ®Google Scholar
• JoyMSHoganSLJennetteJCFalkRJNachmanPHA pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitisNephrol Dial Transplant2005202725273216188901
   PubMed Web of Science ®Google Scholar
• WalshMMerkelPAMahrAJayneDEffects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysisArthritis Care Res (Hoboken)2010621166117320235186
   PubMed Web of Science ®Google Scholar
• McKinneyEFLyonsPACarrEJA CD8+ T cell transcription signature predicts prognosis in autoimmune diseaseNat Med20101658659120400961
   PubMed Web of Science ®Google Scholar
• PepperRJHamourSChaveleKMLeukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritisKidney Int2013831150115823423260
   PubMed Web of Science ®Google Scholar
• TamFWSandersJSGeorgeAUrinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitisNephrol Dial Transplant2004192761276815353578
   PubMed Web of Science ®Google Scholar
• HiemstraTFWalshMMahrAMycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trialJAMA20103042381238821060104
   PubMed Web of Science ®Google Scholar
• PagnouxCMahrAHamidouMAAzathioprine or methotrexate maintenance for ANCA-associated vasculitisN Engl J Med20083592790280319109574
   PubMed Web of Science ®Google Scholar
• [No authors listed]The Wegener’s granulomatosis etanercept (WGET) research group. Etanercept plus standard therapy for Wegener’s granulomatosisN Engl J Med200535235136115673801
   PubMed Web of Science ®Google Scholar
• MetzlerCMiehleNMangerKElevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosisRheumatology (Oxford)2007461087109117519271
   PubMed Web of Science ®Google Scholar
• SmithRMJonesRBGuerryMJRituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum2012643760376922729997
   PubMed Web of Science ®Google Scholar
• Cartin-CebaRGolbinJMKeoghKARituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single centerArthritis Rheum2012643770377822730028
   PubMed Web of Science ®Google Scholar
• GuillevinLPagnouxCKarrasARituximab versus for maintenance in ANCA-associated vasculitis. A prospective study in 117 patientsPresse Med201342679
   Google Scholar
• Cambridge University Hospitals NHS Foundation TrustRituximab Vasculitis Maintenance Study (RITAZAREM) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01697267?term=RITAZAREM&rank=1. NLM identifier: NCT01697267Accessed July 9, 2013
   Google Scholar
• MolloyESCalabreseLHProgressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapiesArthritis Rheum2012643043305122422012
   PubMed Web of Science ®Google Scholar
• BesadaEKoldingsnesWNossentJCLong-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centreRheumatology (Oxford)2013522041204723934313
   PubMed Web of Science ®Google Scholar
• McGregorJGHoganSLHuYGlucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody diseaseClin J Am Soc Nephrol2012724024722134625
   PubMed Web of Science ®Google Scholar
• De JoodeAAESandersJSCohen TervaertJWStegemanCRandomized clinical trial of extended versus standard azathioprine maintenance therapy in newly diagnosed PR3-ANCA positive vasculitis patients at high risk for disease relapsePresse Med201342680 French
   Web of Science ®Google Scholar
• ZycinskaKWardynKAZielonkaTMKrupaRLukasWCo-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvementEur J Med Res200914Suppl 426526720156769
   PubMedGoogle Scholar
• StegemanCATervaertJWde JongPEKallenbergCGTrimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study GroupN Engl J Med199633516208637536
   PubMed Web of Science ®Google Scholar
• HolleJUDubrauCHerlynKRituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestationsAnn Rheum Dis20127132733322021864
   PubMed Web of Science ®Google Scholar
• TaylorSRSalamaADJoshiLPuseyCDLightmanSLRituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosisArthritis Rheum2009601540154719404964
   PubMed Web of Science ®Google Scholar
• JoshiLLightmanSLSalamaADRituximab in refractory ophthalmic Wegener’s granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effectiveOphthalmology20111182498250321907416
   PubMed Web of Science ®Google Scholar
• LangfordCASnellerMCHallahanCWClinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosisArthritis Rheum199639175417608843868
   PubMedGoogle Scholar
• HoffmanGSThomas-GolbanovCKChanJAkstLMEliacharITreatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilationJ Rheumatol2003301017102112734898
   PubMed Web of Science ®Google Scholar
• NouraeiSAObholzerRIndPWResults of endoscopic surgery and intralesional steroid therapy for airway compromise due to tracheobronchial Wegener’s granulomatosisThorax200863495217573443
   PubMed Web of Science ®Google Scholar
• HarperLSavageCOANCA-associated renal vasculitis at the end of the twentieth century – a disease of older patientsRheumatology (Oxford)20054449550115613403
   PubMed Web of Science ®Google Scholar
• MukhtyarCGuillevinLCidMCEULAR recommendations for the management of primary small and medium vessel vasculitisAnn Rheum Dis20096831031718413444
   PubMed Web of Science ®Google Scholar
• FaurschouMMellemkjaerLSorensenIJIncreased morbidity from ischemic heart disease in patients with Wegener’s granulomatosisArthritis Rheum2009601187119219333952
   PubMed Web of Science ®Google Scholar
• MoranSLittleMARenal transplantation in antineutrophil cytoplasmic antibody-associated vasculitisCurr Opin Rheumatol201426374124257368
   PubMed Web of Science ®Google Scholar
• AstenPBarrettJSymmonsDRisk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseasesJ Rheumatol1999261705171410451066
   PubMed Web of Science ®Google Scholar
• SetshediMEpsteinDWinterTAUse of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort studyJ Gastroenterol Hepatol20122738538921793904
   PubMed Web of Science ®Google Scholar
• LapraikCWattsRBaconPBSR and BHPR guidelines for the management of adults with ANCA associated vasculitisRheumatology (Oxford)2007461615161617804455
   PubMed Web of Science ®Google Scholar
• BarthMJCzuczmanMSOfatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemiaFuture Oncol201391829183924295413
   PubMed Web of Science ®Google Scholar
• HoldenNJWilliamsJMMorganMDANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular processAnn Rheum Dis2011702229223321859691
   PubMed Web of Science ®Google Scholar
• KrumbholzMSpecksUWickMBAFF is elevated in serum of patients with Wegener’s granulomatosisJ Autoimmun20052529830216242914
   PubMed Web of Science ®Google Scholar
• BaderLKoldingsnesWNossentJB-lymphocyte activating factor levels are increased in patients with Wegener’s granulomatosis and inversely correlated with ANCA titerClin Rheumatol2010291031103520582728
   PubMed Web of Science ®Google Scholar
• DaridonCBlassfeldDReiterKEpratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosusArthritis Res Ther201012R20421050432
   PubMed Web of Science ®Google Scholar
• WallaceDJKalunianKPetriMAEfficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyAnn Rheum Dis20147318319023313811
   PubMed Web of Science ®Google Scholar
• LangfordCAMonachPASpecksUAn open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s)Ann Rheum Dis1292013 [Epub ahead of print.]
   Google Scholar
• Cambridge University Hospitals NHS Foundation TrustAlemtuzumab for ANCA Associated Refractory Vasculitis (ALEVIATE) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01405807?term=NCT01405807&rank=1. NLM identifier: NCT01405807Accessed July 28, 2011
   Google Scholar
• ReichKLangleyRGPappKAA 52-week trial comparing briakinumab with methotrexate in patients with psoriasisN Engl J Med20113651586159622029980
   PubMed Web of Science ®Google Scholar
• LeonardiCMathesonRZachariaeCAnti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasisN Engl J Med20123661190119922455413
   PubMed Web of Science ®Google Scholar
• PappKALeonardiCMenteABrodalumab, an anti-interleukin-17-receptor antibody for psoriasisN Engl J Med20123661181118922455412
   PubMed Web of Science ®Google Scholar
• KarstenCMKohlJThe immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseasesImmunobiology20122171067107922964232
   PubMed Web of Science ®Google Scholar
• LaurinoSChaudhryABoothAConteGJayneDProspective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvementNephrol Dial Transplant2010253307331420368305
   PubMed Web of Science ®Google Scholar
• SmithJMcDaidJPBhangalGA spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritisJ Am Soc Nephrol20102123123619959716
   PubMed Web of Science ®Google Scholar
• McAdooSPReynoldsJSmithJSpleen tyrosine kinase (SYK) inhibition in experimental autoimmune glomerulonephritis (EAG)Presse Med201342653 French
   Web of Science ®Google Scholar
• WeinblattMEKavanaughAGenoveseMCAn oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritisN Engl J Med20103631303131220879879
   PubMed Web of Science ®Google Scholar
• LamprechtPVoswinkelJLilienthalTEffectiveness of TNFalpha blockade with infliximab in refractory Wegener’s granulomatosisRheumatology (Oxford)2002411303130712422004
   PubMed Web of Science ®Google Scholar
• VenhoffNEffelsbergNMSalzerUImpact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitidesPLoS One20127e3762622629432
   PubMed Web of Science ®Google Scholar
• SaravananVKellyCDrug-related pulmonary problems in patients with rheumatoid arthritisRheumatology (Oxford)20064578778916527879
   PubMed Web of Science ®Google Scholar
• Nordic Pharma SASClinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis (SPARROW) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01446211?term=NCT01446211&rank=1. NLM identifier: NCT01446211Accessed January 19, 2012
   Google Scholar
• University Medical Centre GroningenPrevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Available from: http://www.clinicaltrials.gov/ct2/show/NCT00128895?term=NCT00128895&rank=1. NLM identifier: NCT00128895Accessed November 1, 2011
   Google Scholar
• Human Genome Sciences Inc., a GSK CompanyBelimumab in Remission of VASculitis (BREVAS) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01663623?term=NCT01663623&rank=1. NLM identifier: NCT01663623Accessed February 6, 2014
   Google Scholar